Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure (clinicaltrials.gov) - Sep 25, 2026 - P4 | N=60 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Aug 2030 ➔ Sep 2032 | Trial primary completion date: Aug 2030 ➔ Sep 2032
Monotherapy • Trial completion date • Trial primary completion date • Cardiovascular • Chronic Lymphocytic Leukemia • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Leukemia • Oncology
|